International Collaboration for Innovation: ADMEDES Partners Visit Vico Medical for Technical Exchange
Vickor
Structural Heart Disease Minimally Invasive Intervention Product Developer
Recently, a delegation from ADMEDES, a well-known German medical device manufacturer, visited Wuhan Vickor Medical Technology Co., Ltd. (hereinafter referred to as "Vickor"). The meeting was attended by Wang Xueli, Co-founder & CEO of Vickor, Chen Song, Co-founder & VP, Sun Ming, R&D Director, and relevant project personnel. Both parties held productive discussions on technical cooperation in the field of innovative cardiovascular medical devices.
ADMEDES, as a global leader in the field of cardiovascular medical device manufacturing, has long been renowned in the industry for its advanced technology and exceptional product quality. Its mature metal stent processing platform has provided products or technical services to many leading enterprises in China's cardiovascular industry.Vickor Medical had already established a strategic partnership with ADMEDES in 2021, and the depth and breadth of their business cooperation have been increasing year by year. During this visit, the ADMEDES partners presented their latest technological achievements as well as updates on company and industry developments. They expressed a desire to collaborate with Vickor Medical in areas such as technological innovation, product development, and lean manufacturing processes.
ADMEDES Partners Visit Vickor Medical's Exhibition Hall, Production Workshop, and Key R&D Laboratories, Gaining a Comprehensive Understanding of Vickor Medical’s Product Pipeline and Registration Plans.At the exchange meeting, Vickor's R&D team conducted constructive discussions with ADMEDES partners on the core technology and performance requirements of the company’s key product — a percutaneous interventional aortic valve replacement system (not yet registered in China for the treatment of aortic valve regurgitation).At the same time, the two parties conducted an in-depth discussion on how to further promote technological progress and market application in the field of innovative cardiovascular medical devices.
ADMEDES partners spoke highly of Vickor's achievements in the field of innovative cardiovascular medical devices and expressed their anticipation to establish a long-term and stable partnership with Vickor, jointly promoting the innovation, application, and development of cardiovascular medical technologies.
This technical exchange not only enhanced mutual understanding and trust but also laid a solid foundation for deeper cooperation in the future.Vickor will continue to uphold the cooperative concepts of openness, innovation, and pragmatism, adhere to a problem-oriented approach, and pursue development with an international perspective.`, Launching a Combination of Technological Innovation`, providing safer and more effective treatment solutions for patients worldwide.
Since its establishment in 2018, Vickor has always focused on product innovation in the field of minimally invasive interventional treatment for cardiovascular and cerebrovascular diseases, especially structural heart disease. After years of effort, Vickor has successfully developed several innovative medical device products across细分赛道 such as heart failure, congenital heart disease, and valvular heart disease. Among them, D-shant®The atrial shunt device, with its unique innovation and significant therapeutic effects, has been granted the "Breakthrough Device Designation" by the U.S. Food and Drug Administration (FDA), becoming the first atrial shunt product in China to receive this designation; among which, DOCS VALVE®The aortic valve replacement system features bidirectional anchoring technology, combined with differentiated designs such as large-size valve frames and a dual-sheath three-dimensional bending adjustment delivery system. It is expected to become one of the first innovative products approved in China for the percutaneous treatment of aortic regurgitation.
